BXQ-350 is under clinical development by Bexion Pharmaceuticals and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BXQ-350’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BXQ-350 overview

BXQ-350 is under development for the treatment of cancers including glioblastoma, lung squamous cell carcinoma, malignant glioma, pancreatic cancer, prostate cancer, ependymoma, pediatric diffuse intrinsic pontine glioma, diffuse midline glioma (DMG) and other solid tumors and unspecified central nervous system disorders, lysosomal storage disorder and unspecified viral infections. The drug candidate is administered through intravenous injection. The drug candidate is developed based on Dubbed SapC-DOPS technology. BXQ-350 is a nanovesicle formulation of synthetically produced, human lysosomal protein saposin C (sphingolipid activator protein, or SapC, 80 aa) and the phospholipid dioleoylphosphatidylserine (DOPS). BXQ-350 targets phosphatidylserine (PS) lipids.

It was also under development for the treatment of malignant peripheral nerve sheath tumor, head and neck cancer, neuroblastoma, recurrent solid tumors, brain tumor, breast cancer, pineoblasotoma, osteosarcoma.

Bexion Pharmaceuticals overview

Bexion Pharmaceuticals is a healthcare products and services provider that develops therapies. The company primarily focused in discovery and clinical development of life-changing oncology treatments. The company develops and commercializes drugs for the treatment of cancer. Bexion Pharmaceuticals phospholipid dioleoylphosphatidylserine is used for targeting and treating cancers such as glioblastoma multiforme. The company’s BXQ-350 is a formulation of a synthetically produced human lysosomal protein. It operates through cancer institute for the research on BXQ-350 nanovesicle for the treatment of cancer. Bexion Pharmaceuticals is headquartered in Covington, Kentucky, the US.

For a complete picture of BXQ-350’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.